Ram Mukunda will be a speaker at the upcoming CEO Healthcare Symposium in New York on February 12 and February 13, 2018. His presentation will include commentary on the Company’s efforts in developing and commercializing cannabis–based pharmaceuticals including Hyalolex for Alzheimer’s disease.
2018 Key Objectives
“We are preparing the groundwork necessary to prepare Hyalolex, our lead product formulation for Alzheimer’s ready for Phase 2-B human trials. Independent of this, we expect to make the product available through medical dispensaries in select states of the U.S. In addition, we are working on addressing issues specific to the medical cannabis industry such as transactional difficulties, inadequate product labeling, product identification assurance (PIA) and product origin assurance (POA), using distributed ledgers inherent in blockchain technology. We look forward to an exciting 2018 and I wish to thank YJP for the opportunity to speak at their CEO Healthcare Symposium alongside prestigious leaders and innovators in the healthcare industry,” commented Ram Mukunda, CEO.
About the CEO Healthcare Symposium
This event, sponsored by YJP (www.yjp.org) will feature speakers from the hospital, insurance, biotech, pharma, medical device, medtech, senior living, and home care sectors and will bring together top executives from across the healthcare spectrum to discuss the current and future market trends that we are seeing in the industry.